Medical Monitoring News
-
Daxor Corporation to Commence Trading on the Nasdaq Capital Market
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that it will commence trading on The Nasdaq Capital Market effective at the opening of trading on February 2, 2022, transferring the listing of its common stock from the New York Stock Exchange – American. Daxor’s common stock will continue trading under the ticker symbol ...
-
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022. Mr. Feldshuh will provide company updates and key highlights, including a new patent award and progress ...
-
Daxor Announces Key Milestones Achieved for Multicenter BVA-100 Study in Hospitalized Patients With COVID-19
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces patient enrollment is complete and data analysis is underway in preparation for publication of the multi-center observational prospective study utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology in hospitalized COVID-19 patients. NYU Langone Health, Wake ...
-
Daxor Awarded New Patent for Blood Volume Guidance Technology to Improve Treatment & Outcomes
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced that the United States Patent and Trademark Office has issued the company a new patent (U.S. Patent No. 11,204,356 B2) that protects a proprietary clinical guidance system for volume management utilizing unique volume metrics combined with treatment pathways. “We are very excited ...
-
Thermo Fisher Scientific to Present at the 40th Annual J.P. Morgan Healthcare Conference
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 a.m. (EST). Among other topics, Mr. Casper will provide the company's current perspective on its business and expectations ...
-
Thermo Fisher Scientific to Present at the 2022 Goldman Healthcare CEOs Unscripted Conference
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the 2022 Goldman Healthcare CEOs Unscripted Conference on Thursday, January 6, 2022, at 9:00 a.m. (EDT). You can access the webcast of the presentation via the Investors section of our website. About Thermo ...
-
Pronalyse Unveils Protein Drug Modification Analysis to Move Your Drug Development Program Forward
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development service for over 10 years. The company has recently announced Protein Drug Modification Analysis service to help researchers determine the modification type, modification site, and modification structure of protein drugs. Mature protein medicines have complete ...
-
Creative Proteomics Cytokine Announces Cytokine Systemic Lupus Erythematosus Cytokines Assay Solutions
Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative proteomics recently announced high sensitivity and wide detection range quantitative detection for systemic lupus erythematosus related cytokines ...
-
Creative Enzymes Offers the Raw Materials for Sialic Acid Assay Kit Manufacture
Creative Enzymes, the world’s leading diagnostic enzyme production company, has been committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained a solid reputation. Recently, Creative Enzymes announced the raw ...
-
U.S. FDA approves Xarelto to treat venous thromboembolism (VTE) and to prevent VTE in children
Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age Convenient liquid formulation advances standard of care for children; alleviates administration challenges found with injectable ...
By Bayer AG
-
Thermo Fisher Scientific Updates TaqMan SARS-CoV-2 Mutation Panel to Enable Direct Identification of Omicron Variant
Thermo Fisher Scientific, the world leader in serving science, today announced an update to its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel to enable direct detection of the Omicron SARS-CoV-2 variant. The panel is designed with a customizable menu of real-PCR genotyping assays to accurately identify known SARS-COV-2 variants in just over an hour. South African researchers first ...
-
Bayer receives positive CHMP opinion for finerenone as a new treatment for adult patients with chronic kidney disease associated with type 2 diabetes
Finerenone, a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is recommended by CHMP for marketing authorization for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) CHMP opinion is based on the results of the Phase III FIDELIO-DKD study investigating the efficacy and safety of finerenone on kidney and cardiovascular outcomes in patients ...
By Bayer AG
-
Profacgen Helps Accelerate GPCR Study with Various Services
Profacgen, a global provider of drug screening and profiling services that offers a comprehensive panel of services designed to speed and simplify drug discovery research, now offers professional high-throughput GPCR screening services for identification of potential GPCR-targeting drugs. G protein-coupled receptors (GPCRs) are also known as seven-transmembrane domain receptors. They are ...
By Profacgen
-
Creative Biostructure Supplies MagHelix™ Zebrafish Screening Platform for Drug Discovery
Creative Biostructure, a biotechnology company specialized in structural science field, applies its expertise in structural biology and membrane proteins to the drug discovery process and has established ultimate platforms for structure accelerated drug discovery. This newly established MagHelix™ Zebrafish Screening Platform is an excellent choice for building disease models and screening ...
-
Creative BioMart Established a Novel Sub-brand Creative BioMart Recombinant Allergen
Creative BioMart, an internationally recognized leading supplier of recombinant proteins, recently established a novel sub-brand “Creative BioMart Recombinant Allergen” that focuses on allergen-related study. Allergy is a common hypersensitivity disease in the world. It can be treated by allergen-specific immunotherapy (AIT). Natural allergen extracts do not meet the regulatory ...
-
CDC Lowers Blood Lead Reference Value for Children in Puerto Rico and Across the Nation
The Centers for Disease Control and Prevention (CDC) announced in late October that it had lowered the blood lead reference value (BLRV) for children in response to Lead Exposure Prevention and Advisory Committee (LEPAC) recommendations. The BLRV is now 3.5 µg/dL, down from the previous 5 µg/dL. The new BLRV is intended to identify children with higher levels of lead in their blood ...
-
The Newly Developed Metabolomics Platform Brings New Insights into Enteroaggregative E. coli
With years of experience in metabolomics services, Creative Proteomics has developed a microbial metabolome analysis platform dedicated to providing high-quality, personalized microbial metabolomics services and reliable data support to clients worldwide. Microorganisms have existed on Earth for at least 3.8 billion years and are found in almost all corners of the biosphere. The diversity of ...
-
Creative Proteomics Pronalyse Releases Charge Heterogeneity Analysis Service for Protein Drug Discovery
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO with rich experience in providing drug development services for over 10 years. To assist customers in understanding the changes in protein charge heterogeneity throughout manufacturing and purification, Creative Proteomics Pronalyse offers antibody drug charge variant analysis services using isoelectric focusing or ion ...
-
SARS-CoV-2 Glycosylation Profiling Service Now Available at CD BioGlyco
CD BioGlyco, a biotechnology company that offers a full range of glycobiology-related products, analysis, custom synthesis, and design to help advance glycobiology research, now provides customers with comprehensive and accurate viral glycomics information to speed up the development of vaccines and other therapeutic agents during this COVID-19 pandemic. The US FDA has approved Pfizer and ...
By CD BioGlyco.
-
CD Formulation Launches a Full Range of Drug Analysis Services for the Pharmaceutical Industry
CD Formulation is a service provider for custom pharmaceutical formulation projects, providing diverse CRO services for pharmaceutical formulation development. Earlier this month, the company announced that a full range of drug analysis services are now available for clients across the globe who are engaged with new drug development. The analytical testing of pharmaceutical products involves ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you